Cipher Pharmaceuticals Inc
OTC:CPHRF

Watchlist Manager
Cipher Pharmaceuticals Inc Logo
Cipher Pharmaceuticals Inc
OTC:CPHRF
Watchlist
Price: 10.8 USD Market Closed
Market Cap: $277.6m

Net Margin

25.2%
Current
Declining
by 38.6%
vs 3-y average of 63.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
25.2%
=
Net Income
$17.4m
/
Revenue
$50.1m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
25.2%
=
Net Income
$17.4m
/
Revenue
$50.1m

Peer Comparison

Country Company Market Cap Net
Margin
CA
Cipher Pharmaceuticals Inc
TSX:CPH
376.5m CAD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Higher than 89% of companies in Canada
Percentile
89th
Based on 4 909 companies
89th percentile
25.2%
Low
-9 940 586.9% — -85.9%
Typical Range
-85.9% — 5.5%
High
5.5% — 60 777.6%
Distribution Statistics
Canada
Min -9 940 586.9%
30th Percentile -85.9%
Median -7.8%
70th Percentile 5.5%
Max 60 777.6%

Cipher Pharmaceuticals Inc
Glance View

Market Cap
277.6m USD
Industry
Pharmaceuticals

Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.

CPHRF Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
25.2%
=
Net Income
$17.4m
/
Revenue
$50.1m
What is Cipher Pharmaceuticals Inc's current Net Margin?

The current Net Margin for Cipher Pharmaceuticals Inc is 25.2%, which is below its 3-year median of 63.8%.

How has Net Margin changed over time?

Over the last 3 years, Cipher Pharmaceuticals Inc’s Net Margin has decreased from 32.7% to 25.2%. During this period, it reached a low of 16.3% on Mar 31, 2025 and a high of 112.8% on Sep 30, 2023.

Back to Top